Laura D Attardi

List of Publications by Year in Descending Order

91 papers	14,087 citations	40 h-index	111 g-index
111 ext. papers	16,187 ext. citations	16.7 avg, IF	6.44 L-index

#	Paper	IF	Citations
91	Cell of Origin Influences Pancreatic Cancer Subtype. *Cancer Discovery*, **2021**, 11, 660-677	24.4	19
90	p53 and Tumor Suppression: It Takes a Network. *Trends in Cell Biology*, **2021**, 31, 298-310	18.3	35
89	An anterograde pathway for sensory axon degeneration gated by a cytoplasmic action of the transcriptional regulator P53. *Developmental Cell*, **2021**, 56, 976-984.e3	10.2	2
88	Zmat3 splices together p53-dependent tumor suppression. *Molecular and Cellular Oncology*, **2021**, 8, 1898523	1.2	0
87	A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies. *Developmental Cell*, **2021**, 56, 2089-2102.e11	10.2	6
86	The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. *Nature Communications*, **2021**, 12, 4308	17.4	6
85	Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. *Human Mutation*, **2021**, 42, 223-236	4.7	29
84	P53 orchestrates a complex symphony of cellular processes during oncosuppression. *Molecular and Cellular Oncology*, **2021**, 8, 1852066	1.2	1
83	p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). *Cell*, **2021**, 184, 689-708.e20	36.2	26
82	Puma- and Caspase9-mediated apoptosis is dispensable for p53-driven neural crest-based developmental defects. *Cell Death and Differentiation*, **2021**, 28, 2083-2094	12.7	0
81	Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. *Molecular Cell*, **2020**, 80, 452-469.e9	17.6	14
80	p53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen. *Journal of Cell Biology*, **2020**, 219,	7.3	12
79	Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma. *Head and Neck*, **2020**, 42, 3188-3196	4.2	1
78	Siva plays a critical role in mouse embryonic development. *Cell Death and Differentiation*, **2020**, 27, 297-309	12.7	2
77	Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. *Nature Communications*, **2019**, 10, 4045	17.4	44
76	SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development. *IScience*, **2019**, 20, 14-24	6.1	6
75	The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. *Developmental Cell*, **2019**, 50, 212-228.e6	10.2	31

74	Mutations in PERP Cause Dominant and Recessive Keratoderma. *Journal of Investigative Dermatology*, **2019**, 139, 380-390	4.3	9
73	The role of p53 in developmental syndromes. *Journal of Molecular Cell Biology*, **2019**, 11, 200-211	6.3	26
72	Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders. *Nature*, **2018**, 554, 112-117	50.4	79
71	p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. *Cell Reports*, **2018**, 22, 569-575	10.6	212
70	Neat-en-ing up our understanding of p53 pathways in tumor suppression. *Cell Cycle*, **2018**, 17, 1527-1535	4.7	6
69	Deconstructing networks of p53-mediated tumor suppression in vivo. *Cell Death and Differentiation* , **2018**, 25, 93-103	12.7	105
68	Deciphering p53 signaling in tumor suppression. *Current Opinion in Cell Biology*, **2018**, 51, 65-72	9	121
67	Single Cell Transcriptomics Reveal Abnormalities in Neurosensory Patterning of the Mutant Mouse Ear. *Frontiers in Genetics*, **2018**, 9, 473	4.5	6
66	The p53 family members have distinct roles during mammalian embryonic development. *Cell Death and Differentiation*, **2017**, 24, 575-579	12.7	37
65	Essential role for centromeric factors following p53 loss and oncogenic transformation. *Genes and Development*, **2017**, 31, 463-480	12.6	38
64	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. *Cancer Cell*, **2017**, 32, 460-473.e6	24.3	93
63	is a p53-inducible lincRNA essential for transformation suppression. *Genes and Development*, **2017**, 31, 1095-1108	12.6	124
62	The Transactivation Domains of the p53 Protein. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	63
61	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
60	p73 and FoxJ1: Programming Multiciliated Epithelia. *Trends in Cell Biology*, **2016**, 26, 239-240	18.3	12
59	An inducible long noncoding RNA amplifies DNA damage signaling. *Nature Genetics*, **2016**, 48, 1370-1376	36.3	143
58	Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage. *Nucleic Acids Research*, **2015**, 43, 4447-62	20.1	66
57	The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development. *Cancer Discovery*, **2015**, 5, 622-35	24.4	21

56	Cancer: A piece of the p53 puzzle. *Nature*, **2015**, 520, 37-8	50.4	12
55	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. *Nature Medicine*, **2015**, 21, 1163-71	50.5	275
54	Analysis of p53 transactivation domain mutants reveals Acad11 as a metabolic target important for p53 pro-survival function. *Cell Reports*, **2015**, 10, 1096-109	10.6	35
53	Unravelling mechanisms of p53-mediated tumour suppression. *Nature Reviews Cancer*, **2014**, 14, 359-70	31.3	850
52	Illuminating p53 function in cancer with genetically engineered mouse models. *Seminars in Cell and Developmental Biology*, **2014**, 27, 74-85	7.5	40
51	Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature*, **2014**, 514, 228-32	50.4	101
50	Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. *Nature Medicine*, **2014**, 20, 769-77	50.5	265
49	Guilty as CHARGED: p53's expanding role in disease. *Cell Cycle*, **2014**, 13, 3798-807	4.7	16
48	RB goes mitochondrial. *Genes and Development*, **2013**, 27, 975-9	12.6	12
47	Engaging the p53 metabolic brake drives senescence. *Cell Research*, **2013**, 23, 739-40	24.7	8
46	Tumor suppression: p53 alters immune surveillance to restrain liver cancer. *Current Biology*, **2013**, 23, R527-30	6.3	19
45	Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2013**, 115, 95-103	2	11
44	Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. *Genes and Development*, **2013**, 27, 1016-31	12.6	292
43	TRP53 activates a global autophagy program to promote tumor suppression. *Autophagy*, **2013**, 9, 1440-2	10.2	18
42	Deconstructing p53 transcriptional networks in tumor suppression. *Trends in Cell Biology*, **2012**, 22, 97-106	16.3	136
41	Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer. *Breast Cancer Research*, **2012**, 14, R65	8.3	21
40	Unimpaired skin carcinogenesis in Desmoglein 3 knockout mice. *PLoS ONE*, **2012**, 7, e50024	3.7	9
39	Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. *Cell*, **2011**, 145, 571-83	56.2	369

38	Desmosomes: new perpetrators in tumour suppression. *Nature Reviews Cancer*, **2011**, 11, 317-23	31.3	130
37	PERP regulates enamel formation via effects on cell-cell adhesion and gene expression. *Journal of Cell Science*, **2011**, 124, 745-54	5.3	29
36	Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 17123-8	11.5	60
35	p53 at a glance. *Journal of Cell Science*, **2010**, 123, 2527-32	5.3	263
34	In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. *Carcinogenesis*, **2010**, 31, 1311-8	4.6	58
33	Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. *PLoS Genetics*, **2010**, 6, e1001168	6	56
32	A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell*, **2010**, 142, 409-19	56.2	1648
31	Differential PERP regulation by TP63 mutants provides insight into AEC pathogenesis. *American Journal of Medical Genetics, Part A*, **2009**, 149A, 1952-7	2.5	19
30	Loss of the desmosomal protein perp enhances the phenotypic effects of pemphigus vulgaris autoantibodies. *Journal of Investigative Dermatology*, **2009**, 129, 1710-8	4.3	14
29	SKP-ing TAp63: stem cell depletion, senescence, and premature aging. *Cell Stem Cell*, **2009**, 5, 1-2	18	16
28	Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. *Nature Genetics*, **2008**, 40, 963-70	36.3	285
27	The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. *Molecular Cell*, **2008**, 30, 303-14	17.6	91
26	Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1215-20	11.5	33
25	p63, cell adhesion and survival. *Cell Cycle*, **2007**, 6, 255-61	4.7	38
24	A healthy tan?. *New England Journal of Medicine*, **2007**, 356, 2208-10	59.2	20
23	Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. *Cancer Research*, **2007**, 67, 4648-56	10.1	38
22	Genome-wide analysis of p53 under hypoxic conditions. *Molecular and Cellular Biology*, **2006**, 26, 3492-508	4.8	72
21	Reply to Explaining the biological activity of transactivation-deficient p53 variants. *Nature Genetics*, **2006**, 38, 396-397	36.3	3

20	The requirement for perp in postnatal viability and epithelial integrity reflects an intrinsic role in stratified epithelia. *Journal of Investigative Dermatology*, **2006**, 126, 69-73	4.3	18
19	A new Perp in the lineup: linking p63 and desmosomal adhesion. *Cell Cycle*, **2005**, 4, 873-6	4.7	34
18	Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. *Biochemical and Biophysical Research Communications*, **2005**, 331, 881-90	3.4	133
17	Perp is a p63-regulated gene essential for epithelial integrity. *Cell*, **2005**, 120, 843-56	56.2	258
16	The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. *Nature Genetics*, **2005**, 37, 145-52	36.3	114
15	The role of apoptosis in cancer development and treatment response. *Nature Reviews Cancer*, **2005**, 5, 231-7	31.3	718
14	The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 569, 145-57	3.3	52
13	Probing p53 biological functions through the use of genetically engineered mouse models. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 576, 4-21	3.3	59
12	Mice lacking the p53/p63 target gene Perp are resistant to papilloma development. *Cancer Research*, **2005**, 65, 6551-6	10.1	24
11	p53QS: an old mutant teaches us new tricks. *Cell Cycle*, **2005**, 4, 731-4	4.7	12
10	Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. *Molecular and Cellular Biology*, **2004**, 24, 8884-94	4.8	106
9	APC activators caught by their tails?. *Cell Cycle*, **2004**, 3, 265-6	4.7	37
8	Developmental context determines latency of MYC-induced tumorigenesis. *PLoS Biology*, **2004**, 2, e332	9.7	109
7	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. *Oncogene*, **2004**, 23, 973-80	9.2	93
6	Perp is a mediator of p53-dependent apoptosis in diverse cell types. *Current Biology*, **2003**, 13, 1985-90	6.3	91
5	Multiple response elements and differential p53 binding control Perp expression during apoptosis. *Molecular Cancer Research*, **2003**, 1, 1048-57	6.6	35
4	Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. *Genes and Development*, **2000**, 14, 3037-50	12.6	487
3	A subset of p53-deficient embryos exhibit exencephaly. *Nature Genetics*, **1995**, 10, 175-80	36.3	501

2	In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. *Nature*, **1990**, 344, 126-32	50.4	562
1	A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies		1